ClinicalTrials.gg
CompletedNCT04605107Updated Oct 27, 2020

Biosimilarity Study of IM Injection of Human Chorionic Gonadotrophin After Parenteral Administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA).

A Phase 4 interventional study of Epifasi: Human chorionic gonadotrophin and Pregnyl: Human chorionic gonadotrophin in Infertility, Female, sponsored by Genuine Research Center, Egypt. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-10-27.

Sponsored by Genuine Research Center, Egypt · Phase 4, Interventional, and Health services research

From the registry’s dates

  • Registered 7 years after the study started (first participant enrolled Aug 2013, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.

Enrollment
43rd of 46
60 · median 141
Started
2013
with 1 other
Phase 4
15 of 60
1 open now
Registered
41st of 60
by date

Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 43rd largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2013, is one of 15 in phase 4, and was the 41st registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Infertility, Female with a site in Egypt, or all of them as a file.
02

Study summary

Comparative randomized, single dose, parallel, triple-blinded study in infertile females to evaluate biosimilarity of IM Injection of Human Chorionic Gonadotrophin (HCG) after Parenteral administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA)

Read the detailed description

In this study, the biosimilarity of Human chorionic gonadotropin (HCG) from Epifasi IM Injection (EIPICO Pharma Egypt) and Pregnyl IM Injection (Baxter Pharmaceutical Solutions for Organon, USA) after a single IM dose administration of each to healthy adult will be investigated to determining the study variables: Ovarian Ultrasonic counting mature grafian follicles, Number of retrieved oocytes and their grades.

03

Conditions studied

  • Infertility, Female

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Premenopausal woman between 18 - 40 years of age.
  2. (BMI) of 32 or less.
  3. A menstrual cycle lasting between 21 and 35 days.
  4. Serum hormone levels of FSH 12 IU/L or less, PRL 1040 mIU/L or less, and TSH within the normal range of 0.3- 4.9 mIU/L
  5. Patient having both ovaries and a normal uterine cavity confirmed by hysteroscopy, or hysterosalpingography.
  6. All patients had to be infertile due to at least one of the following causes and must have justified ART (Assisted Reproductive Technology) treatment: tubal factor, mild endometriosis (American Fertility Society classification stage I orII), unexplained infertility, or male factor
  7. Patients achieving good ovarian response and considered to receive hCG for final follicular maturation prior to OPU.
  8. Written and signed by the patient.
  9. Subject does not have allergy to the drugs under investigation.
  10. Medical demographics without evidence of deviation from rather normal medical condition.

Exclusion criteria

Exclusion Criteria:

  1. Patients with low ovarian reserve, as proved by hormonal assays and basal antral follicular count.
  2. More than three previous assisted reproductive technology cycle or treatment with clomiphene citrate or gonadotropins for at least 1 month before screening,
  3. Patients with pelvic abnormality that would interfere with ovarian accessibility for OPU, e.g. ovarian endometriotic cysts or high and retro-uterine ovary.
  4. Patients not achieving a satisfactory ovarian response on ovulation induction, whether poor response (3 or less mature ovarian follicles) or over-response with high likelihood of developing ovarian hyperstimulation syndrome (OHSS) on triggering with HCG.
  5. History of to the study medications or to drugs with similar chemical structure.
  6. Patients unlikely to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and likelihood of not completing the study.
  7. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.
  8. Results of laboratory tests which are .
  9. Acute infection within one week preceding first study drug administration.
  10. History of drug or alcohol abuse.
  11. Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
  12. Subject is on a special diet (for example subject is vegetarian).
  13. Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
  14. Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
  15. Subject has a history of severe diseases which have direct impact on the study.
  16. Participation in a biosimilarity study or in a clinical study within the last 6 weeks before first study drug administration.
  17. Subject intends to be hospitalized within 3 months after first study drug administration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    A test

    Epifasi 5000 I.U. Ampoules

    Drug: Epifasi: Human chorionic gonadotrophin

  • Active comparator
    B reference

    Pregnyl 5000 I.U. Ampoules

    Drug: Pregnyl: Human chorionic gonadotrophin

Interventions

  • DrugEpifasi: Human chorionic gonadotrophin

    IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin

    Also known as: Epifasi

  • IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin

    Also known as: Pregnyl

06

What researchers measure

Primary outcomes

  1. No. of mature follicles

    A dose of Epifasi 5000 I.U. Ampoule was injected to trigger ovulation., At least, one mature follicle should be detected with a diameter of 18 mm or more \& two additional follicles reached a diameter of 16 mm or more. 34 to 36 hours later oocytes were retrieved.

    Time frame: Up to 34-36 hours post dose

Secondary outcomes

  1. Safety Evaluation

    Any reported adverse effect from the patient side or observed by the investigator, Also any abnormal lab finding.

    Time frame: the patient is observed during the whole course of the study and for one month post study

07

Study locations

1 site
  • Genuine Research Center GRC
    Cairo, 11757, Egypt
08

References and documents

Publications

  • Steinijans VW, Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol. 1983;24(1):127-36. doi: 10.1007/BF00613939. PubMed 6832195 ↗
  • Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419. PubMed 3450848 ↗
  • Driscoll GL, Tyler JP, Hangan JT, Fisher PR, Birdsall MA, Knight DC. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod. 2000 Jun;15(6):1305-10. doi: 10.1093/humrep/15.6.1305. PubMed 10831560 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Jan 2015, 16 months.

Of 37 phase 4 interventional studies under Infertility, Female, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Oct 27, 2020
StartActual
Aug 30, 2013
Primary completionActual
Jan 8, 2015
CompletionActual
Mar 8, 2015
Last update
Oct 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04605107
Collaborators
EIPICO PHARMA, EGYPT
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Aug 30, 2013
Primary completion
Jan 8, 2015
Completion
Mar 8, 2015
Last update
Oct 27, 2020

Study contacts

Ahmed Elshafeey, Ph.D. Pharma
study director · Genuine Research Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chorionic Gonadotropin

Start the discussion